☰
Reportedly, Novartis made an announcement that the COMBI-I study in its third phase that does evaluation of investigational immunotherapy spartalizumab (PDR001), combined with the targeted therapies Mekinist (trametinib) and Tafinlar (dabrafenib) did not produce a primary result of progression-free, investigator-assessed survival.
As per the trusted sources, the trail was conducted on untreated patients with metastatic (Stage IV) BRAF V600 or unresectable (Stage IIIC) mutation-positive cutaneous melanoma, in comparison with Tafinlar + Mekinist treatment alone. Tafinlar and Mekinist are medicines prescribed in combination to treat patients with skin cancer- melanoma.
John Tsai, MD, Chief Medical Officer and Head of Global Drug Development at Novartis states that although the COMBI-I trial did not get to its primary outcome, the report’s analysis offers some important insights of its part like the investigational immunotherapy spartalizumab could possibly contribute to the future cancer therapy combinations. Besides this, it also highlights the significance of Tafinlar + Mekinist for these patients as estimated in the past.
He further added that Novartis is fully dedicated towards curing melanoma patients through ongoing study and they would continue to provide the approved combination therapy Tafinlar + Mekinist to patients across the globe.
He added that they at Novartis extend gratitude to the patients and investigators who took part in the COMBI-I study and claimed that their collaboration has raised understanding of spartalizumab and its potential role in future cancer treatments at Novartis.
Reportedly, COMBI-I study investigators and people at Novartis will continue to analyze the data to gain more information from the results, which are likely to be taken forward to a presentation at a future medical meeting.
Novartis continues to search for more uses of immunotherapy in cancer treatment, along with the latest ongoing development of spartalizumab, across a plethora of tumors.
Source credits-
An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...
Pacific Island nations have reportedly pushed Japan to postpone the release of Fukushima nuclear power plant wastewater due to concerns that it may pollute fishing grounds. An appeal was made on Wednesday when Japan announced that treated sewage f...
Danone, the French bottled water and yogurt firm, is reportedly being sued in court by three environmental activists’ groups for failing to cut its plastic footprint significantly. According to the groups, the maker of Evian and Volvic miner...
Bosch, the German technology company, has reportedly expanded its security footprint in the ridesharing market with the launch of its latest security dashcams. At CES 2023, Las Vegas, the German tech firm unveiled a new integrated smart camera on ...
Australia's Prime Minister Anthony Albanese has reportedly denied rumors that Rio Tinto and its partners could receive a $450 million settlement for the Gladstone power station, which would bring the total compensation for the coal price limit to...
Businesses in the UK are still reportedly grappling after two years following the beginning of post-Brexit trading, as suggested by a new report. According to the British Chambers of Commerce (BCC), firms are still battling increased red tape and ...
© 2023 aeresearch.net. All Rights Reserved.